FDA flags off-label weight-loss injection use; adverse events reported for semaglutide, tirzepatide

The FDA has issued an alert about the growing use of weight-loss injections without a medical indication, citing reports of adverse effects linked to semaglutide and tirzepatide. The phenomenon reflects widespread off-label or unapproved use of these drugs, raising safety concerns. Regulatory action or updated guidance may follow, but specifics of the alert and the scope of adverse events remain unclear.